First of a kind in HIV treatment.
The Food and Drug Administration has approved Atripla Tablets, a fixed-dose combination of three widely used antiretroviral drugs in a single tablet for the treatment of HIV-1 infection in adults. Atripla is to be taken once a day alone or in combination with other antiretroviral products.
D000225:Adenine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000480:Alkynes; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D048588:Benzoxazines; D003521:Cyclopropanes; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017277:Drug Approval; D004338:Drug Combinations; D000068257:Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; D000068679:Emtricitabine; D015658:HIV Infections / Q000188:drug therapy*; D015497:HIV-1; D006801:Humans; D063065:Organophosphonates / Q000008:administration & dosage / Q000627:therapeutic use*; D010078:Oxazines / Q000008:administration & dosage / Q000627:therapeutic use*; D000068698:Tenofovir; D014481:United States; D014486:United States Food and Drug Administration
D000480:Alkynes; D019380:Anti-HIV Agents; D048588:Benzoxazines; D003521:Cyclopropanes; D004338:Drug Combinations; D000068257:Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; D063065:Organophosphonates; D010078:Oxazines; D003841:Deoxycytidine; D000068698:Tenofovir; D000068679:Emtricitabine; D000225:Adenine; C098320:efavirenz